AIM: To assess the combined use of tetracycline (TTC) and ethylenediaminetetraacetic acid (EDTA) on clot formation, considering that EDTA may neutralize TTC acidity.METHODS: Planed human tooth roots were treated with saline solution, EDTA, TTC and their combination (EDTA followed by TTC and TTC before EDTA). Fresh human blood was applied on the conditioned surfaces to check clot adhesion and stabilization. A previously calibrated (kappa = 0.93) and blinded examiner scored scanning electron micrographs of the samples. Statistical analyses were performed using one-way ANOVA and Tukey's test.RESULTS: Application of TTC before EDTA presented the best results with the highest number of cells adhered to the root surface (p=0.046). Use of EDTA alone and EDTA before TTC disturbed clot stabilization when compared to control group (p<0.01).CONCLUSIONS:The use of TTC before EDTA seems to be able to keep blood cells viable to establish an organized clot and could be used by clinicians together with the conventional mechanical root scaling and planing.
The aim of this study was to evaluate the presence of class I anti-HLA alloantibodies in patients infected by HIV-1 and relate it with the different clinical courses of the disease. Blood samples were collected in EDTA tubes from 145 individuals. HIV-1 infection was confirmed by ELISA test. The presence of class I anti-HLA alloantibodies and HLA allele's were determined. Clinical evolution was set as fast (<1 year between diagnostic and death), moderate (1-3 years) or slow (>3 years). Class I anti-HLA alloantibodies presence was lower in healthy individuals than in those infected by HIV-1 (4.2% against 32.4%). However, an equal distribution of these alloantibodies was found among the individuals infected, independent on the clinical evolution. Thus, class I anti-HLA alloantibodies was not a determinant factor for patient worsening.
O objetivo deste estudo foi avaliar a presença de aloanticorpos anti-HLA classe I em pacientes infectados pelo HIV-1 e relacioná-la aos diferentes cursos clínicos da doença. Amostras de sangue de 145 indivíduos HIV positivo foram coletadas em tubos com EDTA. A infecção pelo HIV-1 foi confirmada por teste ELISA e a presença de aloanticorpos anti-HLA classe I determinada em seguida. A evolução clínica foi definida como rápida (<1 ano entre diagnóstico e morte), moderada (1-3 anos) ou lenta (>3 anos). A presença de aloanticorpos anti-HLA classe I foi menor em indivíduos saudáveis em relação aos infectados pelo HIV-1 (4,2% contra 32,4%). Porém, a distribuição destes aloanticorpos entre os indivíduos infectados foi igual, independente da evolução clínica. Deste modo, a presença de aloanticorpos anti-HLA classe I não é um fator determinante na piora clínica do paciente.